Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications

Menelaos Papoutselis; Emmanouil Spanoudakis

doi:10.1016/j.clml.2020.01.006

Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications

Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):358-365. doi: 10.1016/j.clml.2020.01.006. Epub 2020 Mar 6.

Authors

Menelaos Papoutselis¹, Emmanouil Spanoudakis²

Affiliations

¹ Division of Haematology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
² Division of Haematology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. Electronic address: espanoud@med.duth.gr.

PMID: 32234294
DOI: 10.1016/j.clml.2020.01.006

Abstract

Multiple myeloma (MM) is an incurable B-cell malignancy. The immunotherapeutic approach for MM therapy is evolving. The Cd1d/invariant natural killer T-cell/glycolipid immune axis belongs to the innate immunity, and we have highlighted role in myeloma pathogenesis in the present study. The recent development of the chimeric antigen receptor (CAR19)-invariant natural killer T-cells resulted in our renewed interest in this immune system and offer new perspectives for future anti-MM immunotherapies.

Keywords: CAR-iNKT cells; Haematologic malignancy; Immunotherapy; Innate immunity; Lymphocyte.

Publication types

Review

MeSH terms

Antigens, CD1d / immunology*
Glycolipids / immunology*
Humans
Immunity, Innate*
Immunotherapy, Adoptive*
Multiple Myeloma* / immunology
Multiple Myeloma* / therapy
Natural Killer T-Cells / immunology*

Substances

Antigens, CD1d
CD1D protein, human
Glycolipids